Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.

Neuromuscular disorders : NMD - 1 Feb 2010

Popplewell Linda J, Adkin Carl, Arechavala-Gomeza Virginia, Aartsma-Rus Annemieke, de Winter Christa L, Wilton Steve D, Morgan Jennifer E, Muntoni Francesco, Graham Ian R, Dickson George

Abstract excerpt

Duchenne muscular dystrophy (DMD) is caused by the lack of functional dystrophin protein, most commonly as a result of a range of out-of-frame mutations in the DMD gene. Modulation of pre-mRNA splicing with antisense oligonucleotides (AOs) to restore the reading frame has been demonstrated in vit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dystrophin
Share to Gene Targeting

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Mice, Transgenic

Share to Morpholines

Share to Morpholinos

Share to Muscular Dystrophy, Duchenne

Share to Oligonucleotides, Antisense

Source

Identifiers

PMID: 20079639
DOI: 10.1016/j.nmd.2009.10.013

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20079639-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.PMID 20079639Read ↗

Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Next steps for the optimization of exon therapy for Duchenne muscular dystrophySemantic proximity Read ↗

Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human MuscleSemantic proximity Read ↗

Clinical trials of exon skipping in Duchenne muscular dystrophySemantic proximity Read ↗

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular DystrophySemantic proximity Read ↗

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides.Semantic proximity Read ↗

<i>DMD</i> antisense oligonucleotide mediated exon skipping efficiency is affected by flanking intron retention time and target position within the exonSemantic proximity Read ↗

Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.Semantic proximity Read ↗

In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52–Deficient mdx MouseSemantic proximity Read ↗

Toward an Oligonucleotide Therapy for Duchenne Muscular Dystrophy: A Complex Development ChallengeSemantic proximity Read ↗

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular DystrophySemantic proximity Read ↗

RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.